INS and type 2 diabetes mellitus: Evidence relative to the efficacy of isCGM in improving glycemic outcomes, including a greater TIR, a lower TBR, and a higher reduction in HbA1c levels, are also emerging among non-insulin-treated people with type 2 diabetes [35].